Join BNMS | Print Page | Contact Us | Sign In
News & Press: Latest News

FDA approves Pluvicto for metastatic castration-resistant prostate cancer

29 March 2022   (0 Comments)
Posted by: Caroline Oxley

On March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

See FDA website here for more information:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer

« Back to Index

 

 

© 2013 BNMS unless otherwise stated.
The BNMS is a registered as a company in England and Wales with number 08082786.  The BNMS is a charity governed by the rules of the Charity Commission for England and Wales - Registered Number 1150234.  Registered Office: The Royal College of Physicians, 11 St. Andrew's Place, Regent's Park, London NW1 4LE.
The British Nuclear Medicine Society is not able to give specific clinical advice to members of the public. If you are concerned about your scan or therapy please seek the opinion of a nuclear medicine clinician where you were seen or the clinician who referred you to the department or your GP.
Enquiries related to issues such as internships and work experience opportunities, should be directed to the relevant professional body e.g., for radiologists, this will be the Royal College of Radiologists.